Open Collections

UBC Faculty Research and Publications

Are claims for newer drugs for overactive bladder warranted? Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 93 considers whether claims for newer drugs for overactive bladder are warranted. Conclusions: All drugs for overactive bladder have limited short-term potential benefit and appreciable risk of adverse effects. There is insufficient evidence that benefits of long-term treatment outweigh harm for any overactive bladder drug. Claims of superiority for any antimuscarinic drug (including fesoterodine and oxybutynin chloride gel) over the others are not warranted due to methodological shortcomings of available RCTs. Mirabegron is a poor alternative due to its lack of an efficacy advantage and cardiac risks. Recent observational studies suggest that all longterm anticholinergic drugs increase risk of dementia.

Item Metadata

Title
Are claims for newer drugs for overactive bladder warranted?
Alternate Title
Therapeutics Letter 93
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2015-02
Description
Therapeutics Letter 93 considers whether claims for newer drugs for overactive bladder are warranted. Conclusions: All drugs for overactive bladder have limited short-term potential benefit and appreciable risk of adverse effects. There is insufficient evidence that benefits of long-term treatment outweigh harm for any overactive bladder drug. Claims of superiority for any antimuscarinic drug (including fesoterodine and oxybutynin chloride gel) over the others are not warranted due to methodological shortcomings of available RCTs. Mirabegron is a poor alternative due to its lack of an efficacy advantage and cardiac risks. Recent observational studies suggest that all longterm anticholinergic drugs increase risk of dementia.
Subject
Drug-Related Side Effects and Adverse Reactions; Drug Safety; Fesoterodine; Mirabegron; Muscarinic Antagonists; Oxybutynin; Urinary Bladder, Overactive
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433672
URI
http://hdl.handle.net/2429/85082
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International